ERBB2 and breast carcinoma: Among the HER2+ breast cancer cases, 51% showed the HER2-enriched subtype, and the complete pathologic response rate to HER2-targeted neoadjuvant therapy was significantly higher in the HER2-enriched subtype than in the luminal A and B subtypes [31].